Localized diseases such as bacterial infections, heart dysfunction and cancer are mainly treated through orally or intravenously administered medicines. Those ways of administration often require high doses of medications as the drugs must circulate through the bloodstream before reaching their targets, making them susceptible to the body clearance systems. These administration methods carry inherent challenges, including risks of side effects and obstacles to effective drug absorption: acidic gastric conditions and intestinal membrane barrier for oral route or immune response triggering and first pass metabolism for intravenous way. Recent researches highlight the potential of the pulmonary route as a more efficient alternative for drug delivery, especially for conditions affecting the lungs and heart. This approach allows for the aerosolization or nebulization of nanomedicines, enabling them to reach the deep lung, where the epithelial barrier is just 0.2 µm thick. In this poster, we will present those promising researches about delivering nanomedicines through the pulmonary route to treat lungs diseases and other organs such as the heart. An example of this delivery strategy is targeting doxorubicin cardiotoxicity, a widely used anticancer agent which disrupt lysosomal function in cardiomyocytes. To counteract these side effects, silica nanoparticles grafted with poly(lactic-co-glycolic acid) (PLGA) had been developed by Santin et al. These nanoparticles, characterized by a zeta potential of -31 mV and a hydrodynamic diameter of 25 nm, are designed for nebulization and effective delivery to cardiac tissues. In vitro and in vivo studies demonstrated that these PLGA nanoparticles can restore lysosomal activity in cardiomyocytes, mitigating the toxic effects of doxorubicin. This innovative pulmonary delivery system represents a promising avenue for enhancing therapeutic efficacy while minimizing systemic side effects in cardiac applications.